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Viral load (VL) quantification is considered an integral part of the standard care in human
immunodeficiency virus (HIV) infected individuals but in Nigeria as in most of sub-Saharan Africa, this has
not reached the majority of patients.
We report the first field application of the NucliSens EasyQ HIV-1 platform for the real time
quantification of HIV-1 VL combining NASBA amplification and real time detection with molecular beacons
among HIV-1 infected individuals in north central Nigeria where the predominant HIV-1 subtypes are
CRF02_AG and G. CD4 counts were enumerated using a fluorescence-activated cell sorter system.
Of one hundred and forty nine (n=149) plasma sample from patients with mean age of 32 years and
made up of 77 males and 72 females, fifty {n = 50 (37.9%); 28 males and 22 females}had VLs below the lower
detection limit (LDL=25 IU/ml) set by the assay while eighty- two {n = 82 (62.1%); 39 males and 43
females}had VL levels above the LDL. Furthermore, 13 of 82 (15.9%) patients with viral loads above the LDL
had VLs between 26-1000 IU/ml while 69 (84.1%) had VLs of 1001-2400000 IU/ml. 17 (11.4%) of the
samples could not be analyzed due to poor viral amplification. Among individuals with both CD4 and VL
results (n=56), those with CD4 of 1-418 cell/µl presented with higher VL usually above 45,000 IU/ml when
compared with those with CD4 of over 500 cell/µl.
Our findings highlight the pattern, usefulness and feasibility of VL quantification by NucliSens
EasyQ in monitoring HIV-1 patients in Nigeria.






Nigeria has the third highest burden of the human
immunodeficiency virus (HIV) infection in the
world, with people living with HIV estimated to
total over 4.0 million (1). In 2002, the
implementation of one of Africa's largest
antiretroviral (ARV) treatment programmes was
commenced in Nigeria (2). A standard, functional
and effective laboratory monitoring system must be
put in place for ARV-treatment programs to be
successful. Many clinical and laboratory markers
including circulating CD4 and CD8 T cell counts,
p24 antigen and ß-2 microglobulin quantification
have been used for determining the prognosis in
HIV-1 infection (3, 4). Direct HIV-1 RNA
quantification has recently become a useful method
for assessing and monitoring HIV-1 disease
progression. Viral RNA in plasma directly reflects
the titer of HIV-1 during infection and is a better
predictor of subsequent risk of AIDS or death than
the other markers cited above (4). As a direct
measurement of circulating virus, HIV-1 viral load
is expected to give complementary information to
other markers that monitor the
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status, as lymphocytes subsets cell counts and seric
ß-2 microglobulin levels. Besides, viral load (VL)
has enabled physicians to monitor the efficacy of
antiretroviral therapies since it has been shown that
treatment failures correlates with a rapid and
dramatic decrease in the HIV-1 RNA level and vice
versa (5).
Tremendous strides have been made in treating and
monitoring HIV-1 infection. Combination
antiretroviral (ARV) drugs therapy suppresses virus
replication, delays disease progression, and reduces
mortality (5, 6). Plasma VL assays are used in
combination with CD4 cell counts to determine
when to initiate therapy and detect when a regimen is
failing. Recently, the United States Department of
Health and Human Services guidelines advocate the
use of plasma viral load testing when considering
ART initiation, monitoring response to therapy, and
instituting a change in drug regimen (6).
Unfortunately, the full benefits of antiretroviral drugs
and monitoring tests have not yet reached the
majority of HIV infected patients who live in sub-
Sahara Africa where the impact of the disease is
greatest and where differences in the HIV-1
genotypes could introduce a bias in the assay (1).
Numerous countries in sub-Saharan Africa have
+
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3,000,000 IU/ml) set by the EasyQ assay. Statistical
analyses were performed on the results of samples
with valid NucliSENS EasyQ HIV-1 results.
The CD4 values for fifty six (n
= 56) of the HIV patients with known viral load were
also enumerated using our previous method (12).
Briefly, we used a superior fluorescence-activated
cell sorter system (FACScount, Becton Dickenson
FACScount, Canada) according to manufacturer's
instructions. This system quantifies CD4 T
lymphocytes as absolute numbers of lymphocytes
per L of blood and results recorded in an automated
fashion. The CD4 and VL were compared using chi-
Square test at 95% confidence level. All the
participants in this study signed informed consent
form after the purpose of the study was explained to
them by our counselors and the study protocol was
approved by the research committee of Innovative
Biotech.
A total of 149 clinical samples from patients aged
between 5 and 59 years (mean = 32 years) and made
of 77 males and 72 females respectively were
available for HIV-1 viral load quantitation.
Seventeen (n = 17; 11.4%; 10 males and 7 females)
samples could not be included in the analysis because
of invalid EasyQ results arising from poor viral RNA
amplification. The results of the remaining 0ne
hundred and thirty two (n = 132) samples were
grouped into two: Group 1, had viral loads below
detection levels (LDL = 25 IU/ml) while group 2
were those above detection limit (below the detection
limit is designated LDL by the analyzer). Fifty {n =
50 (37.9%); 28 males and 22 females} had viral
loads below the detection limit set by the assay while
eighty- two {n = 82 (62.1%); 39 males and 43
females} had viral loads above the detection limit set
by the assay. Furthermore, 13 of 82 (15.9%) patients
in group 2 had viral loads between 26 and 1000 IU/ml
while 69 (84.1%) had viral loads of 1001-2400000
IU/ml. 10 of 132 (13.2%) patients had HIV-1 viral
load of 50000-2400000IU/ml. Of the 56 individuals
with both CD4 and viral load results, those with
CD4 values of 1 to 418 cells/µl presented with
higher viral load values of 45,000 IU/ml and above
when compared with those with CD4 values above
500 cells/µl were VLs tended to be nearer the LDLset
by the assay.
It is clear that a highly active antiretroviral treatment
(HAART) is able to reduce viral load and partially
repair the immunological damage caused by HIV-1
infection (13). VLis therefore an important marker of
HIV prognosis and there is a general acceptance










elected to base their treatment follow-up on CD4+
monitoring alone which is known to be inherently
inconsistent and could be misleading (7, 8).
We report the results of the first field performance
and application of the NucliSens EasyQ viral load
assays for the quantitative detection of HIV-1 RNA
in patients infected with HIV-1 in Nigeria where the
predominant subtypes are CRF02_AG and G (9).
The relationship between Cd4 T-cells and viral load
was also assessed.
One hundred and forty nine
(n=149) blood samples were collected by
venepuncture from patients attending our HIV
treatment program at two Innovative Biotech (IBL)
sites in North Central Nigeria (IBL clinic- Keffi and
IBL clinic- Abuja- North central Nigeria) as part of
their treatment monitoring between March 2006 and
October 2007. Five-milliliter EDTA blood samples
were collected and centrifuged, and the plasma was
used for routine HIV-1 VL analysis. In our facility,
VL measurement is considered mandatory for HIV
monitoring. The plasma samples were placed in
NucliSENS lysis buffer after collection and prior to
testing to preserve the nucleic acid of the virus. Only
HIV-1 positive patients were considered for this
study. Individuals with HIV-2 or dual infection were
excluded from the study. The study was cross-
sectional in design.
The NucliSENS
miniMAG platform version 1.0 (revision 1) for
nucleic acid extraction and NucliSENS EasyQ HIV
type 1 (HIV-1) analyzer version 2.0 (revision 0)
(BioMérieux , Boxtel, The Netherlands) were used
for the real time quantification of viral load in plasma
samples by combining NASBA amplification with
molecular beacon (MB) detection technology.
NASBA amplification primers and MB detection
probes were directed towards a conserved region of
the HIV-1 genome. RNA extraction from plasma
samples was performed with a silica-based
procedure using the NucliSens extractor.
Subsequently, NASBA amplification and real-time
detection of HIV-1 RNAand internal calibrator RNA
was performed in a single tube using a temperature-
controlled fluorescence reader. Quantitative results
were calculated using a curve fitting of signal curves
for both the HIV-1 RNA and an internal calibrator.
In a single run, test results were obtained in 90
minutes with less than 30 minutes hands-on time.All
assays were conducted according to the
manufacturer's instructions and good laboratory
practice standards. Further details of the procedure
are as described by Weusten et al, 2002 and Stevens
et al, 2005 (10, 11). All values were reported
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measure of HIV/AIDS disease progression (6, 8). The
NucliSens EasyQ assay has been evaluated in South
Africa and China for the quantification of HIV-1 VL
where the predominant subtype is C and have been
found to be very reliable, effective ,sensitive, specific
and reproducible (11,14,15). This instrument
automates the labor-intensive washing steps typical of
nuclic acid extraction, thereby significantly reducing
hands-on time.The NucliSENS miniMAG-
NucliSENS EasyQ HIV-1 combination provides a
feasible platform for HIV viral load quantification.
The gains of this technology has been reaped by
industrialized countries while countries in sub-Sahara
Africa keep relying on the inherently inconsistent
CD4 counts as a first choice marker in HIV/AIDS
monitoring (8, 10). In Nigeria, to the best of our
knowledge no study has been published describing the
use of the NucliSENS EasyQ real time boom
technology in HIV-1 VL monitoring. We demonstrate
that the NucliSENS EasyQ HIV-1 with its very wide
linear range (25 IU/ml to 3,000,000 IU/ml) is usable
Nigeria. One of the reasons advanced against the use of
the VL test in Nigeria is cost. The NucliSENS EasyQ
is known to be more affordable compared to the Roche
Amplicor (11) and the manufacturers are decreasing
kit costs and in some instances equipment costs for
resource-limited countries, thereby making this more
affordable.
As a result of invalid EasyQ results due to poor viral
RNA amplification, 11.4% of the plasma samples
could not be included in the final analysis. In a related
study, Weusten et al., 2002 (10), had recorded that
16.6% of 218 clinical samples could not be analyzed
for various reasons. 37.9% of our patients (28 males
and 22 females}had VLs below the detection limit set
by the assay. Evidence shows that keeping the VL
levels as low as possible for as long as possible
decreases the complications of HIV disease and
prolongs life (16).
Interestingly,
46 of the 50 patients with LDL were on ART
(lamivudine 150mg, stavudine 30-40mg and
niverapine 200mg) that is known to be able to reduce
VL. The treatment history of the remaining 4 patients
with LDL is unknown to us. On the other hand, 62.1%
of our patients (39 males and 43 females}had viral load
values above the LDL.
Furthermore, 15.9% patients in group 2 had viral loads
between 26 and 1000 IU/ml while 84.1% had VLs of
1001-2300000 IU/ml. We also report that 10 of 132
(13.2%) of our patients had viral RNA of 50000-
2400000IU/ml. Individuals with a lesser or
undetectable VL have lower chances of experiencing
any disease progression while those with very high VL
have higher chances of disease progression. The age
range of the participants in this study was between 5
and 59 years (mean = 32 years).The performance of the
Nuclisens EasyQ HIV-1 assay has been assessed in
+
Therefore, the goal of anti-HIV
treatment is to keep VL for as long as possible below
the limit of what the VL test can detect.
These individuals are at risk of
getting sicker and progressing faster to AIDS.
individuals infected with HIV non-B subtypes that are
predominant in Africa and found to be very reliable
with a wider dynamic range than Amplicor (17). The
Roche Amplicor method is commonly used in Nigeria.
Previous studies have shown that the NucliSens EasyQ
assay correlated significantly with the Roche Amplicor
and it's a more affordable option (11). The standard
Roche Amplicor assay has a linear range of 400 to
750,000 HIV RNA copies/ml while that of the
NucliSENS EasyQ is 25 to 3,000,000 IU/ml. In the
NucliSENS EasyQ assay, the potential for
contamination has been dramatically reduced by using
the automated extraction system. This assay thus
presents a real and superior option for monitoring HIV
load inAfrica where the burden of the disease is highest
and in Nigeria where the predominant HIV subtypes are
CRF02_AG and G (2, 9). In South Africa, HIV VL
monitoring is used to determine the need for changing
to second-line drug regimens (18). In this study, we
observed that HIV-1 infected individuals with CD4
values of 1-to-418 cells/µl presented with significantly
higher (p<0.05) viral load values usually above 45,000
IU/ml when compared with patients having CD4
values of >500 cells/µl who tended to have VLs nearer
the lower detection limit set by the assay. This agrees
with Olsen et al (19) who found that HIV infected
individuals with CD4 count =350 cells/µl were at
increased risk of AIDS or death than those with higher
CD4 counts. It is worth noting that an approximately
inverse relationship of VL to the CD4 T-cell count and
survival time had been observed in around 80% of HIV
infected individuals (20, 21).
We belief that NucliSENS EasyQ assay with respect to
sensitivity, specificity, precision, reproducibility,
dynamic range and linearity be recommended for use in
Nigeria where the predominant HIV subtypes are
CRF02_AG and G (9) and where the burden of the
disease is on the increase for treatment to be
meaningful. This could be used in conjunction with the
already widely used and available CD4 measurement.
The real-time NucliSens EasyQ HIV-1 viral load assay
meets the performance requirements for HIV-1 viral
load monitoring in an HIV non-B subtype crescent like
Nigeria. This paper represents to the best of our
knowledge the first formal description of the
application of the miniMAG-EasyQ-NucliSENS
EasyQ assay in HIVviral load quantification in Nigeria.
Its implemented on a broader scale in Nigeria is
recommended to enable HIV infected individuals
access the gold standard for routine HIV monitoring.
No member of the writing team
owned stock or was employed by the kit manufacturers
mentioned in this article. Some free kits were provided
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